SAB Biotherapeutics Inc Ordinary Shares SABS 深 滬
等待開盤 08-14 09:30:00 美东时间
2.15
-0.010
-0.46%
華盛通- 最 高2.21
- 今 開2.18
- 成交量 7.63万股
- 最 低 2.09
- 昨 收 2.16
- 總市值 1997.11万
- 52周最高 6.60
- 市盈率 靜 --
- 換手率 0.82%
- 52周最低 1.00
- 委 比 -66.24%
- 總股本 928.89万
- 歷史最高 129.00
- 量 比 0.58
- 振 幅 5.56%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $12
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $20 to $12.
08-08 20:02
SAB Biotherapeutics Reports Increased Losses Amid Funding Boost
Sab Biotherapeutics, Inc. ( ($SABS) ) has released its Q2 earnings. Here is a b...
08-08 13:58
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
SAB BIO, a clinical-stage biopharmaceutical company, announced it raised $175 million in an oversubscribed private placement led by strategic investor Sanofi and top-tier biotech investors. The funds will support the pivotal Phase 2b SAFEGUARD study for SAB-142, a human anti-thymocyte immunoglobulin targeting type 1 diabetes, set to begin in Q3 2025. The financing extends the company's operational runway until mid-2028. Key achievements include a...
08-07 11:30
SAB Biotherapeutics Secures $175M in Private Placement
SAB Biotherapeutics ( ($SABS) ) just unveiled an update. On July 21, 2025, SAB ...
07-21 20:27
SAB BIO Raises $175M In Oversubscribed Private Placement To Fully Fund Phase 2b SAFEGUARD Trial For Autoimmune Type 1 Diabetes
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and
07-21 19:36
SAB BIO Announces Oversubscribed $175 Million Private Placement
SAB BIO, a clinical-stage biopharmaceutical company, secured $175 million in a private placement through战略投资者Sanofi和其他新投资者的参与。此次融资将主要用于完成关键的Phase 2b SAFEGUARD研究，评估SAB-142对延缓新诊断自身免疫性1型糖尿病进展的效果，并将公司的现金流延长至2028年中期。此外，若期权行使，可能额外获得2.84亿美元。公司专注于开发人源抗胸腺细胞免疫球蛋白（hIgG）以治疗自身免疫性疾病。
07-21 11:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Longevity Health Holdings (NASDAQ:XAGE) shares moved upwards by 55.5% ...
05-22 05:06
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
HC Wainwright & Co. Assumes SAB Biotherapeutics at Buy, Announces Price Target of $10
HC Wainwright & Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $10.
05-15 00:56
